Treatment with proteasome inhibitor MG132 during cloning improves survival and pronuclear number of reconstructed rat embryos.
In several mammalian species including rats, successfully cloned animals have been generated using somatic cell nuclear transfer (SCNT). However, in the case of rats, additional treatment with MG132, a proteasome inhibitor, before enucleation of oocytes seems to be required for successful cloning because ovulated rat oocytes are spontaneously activated, and hence, their suppression is the key to successful cloning. A previous study on rats demonstrated that matured oocytes potentially possess lower cytostatic factor (CSF) activity compared to mouse oocytes, resulting in a low incidence of premature chromosome condensation in the reconstructed embryos after SCNT. It is known that mice having more than two pronuclei are generally observed in nuclear-transferred oocytes after induction of premature chromosome condensation, which implies successful reprogramming. This leads us to the hypothesis that MG132 treatment affects not only the inhibition of spontaneous activation but also the reprogramming and developmental ability of reconstructed rat embryos. If so, prolonged MG132 treatment during and/or after SCNT may further improve the survivability. However, the effect of MG132 treatment on reconstructed embryos after SCNT has been very limited in rats and other species. We show here that prolonged MG132 treatment during and after SCNT improves survival and the number of pronuclei in reconstructed rat embryos after activation. These reconstructed embryos treated before, during, and after SCNT showed significantly higher p34(cdc2) kinase activity involving CSF activity compared to that of the control embryos. On the other hand, p34(cdc2) kinase activity was not recovered in nuclear-transferred oocytes without MG132, which suggested that the enucleation had detrimental effects on the development of reconstructed oocytes. Taken together, MG132 treatment during SCNT increases survival and pronuclear numbers in reconstructed rat embryos via maintenance of high CSF activity. The data suggest that MG132 treatment is indispensable for at least rat SCNT.
Nakajima
Noriaki
N
Laboratory of Animal Reproduction, Graduate School of Veterinary Science, Azabu University, Sagamihara, Kanagawa, Japan.
Inomata
Tomo
T
Ito
Junya
J
Kashiwazaki
Naomi
N
D000818:Animals; D019976:Cloning, Organism / Q000379:methods*; D018844:Cyclin-Dependent Kinases / Q000187:drug effects / Q000378:metabolism*; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology*; D046149:Embryo Culture Techniques; D004622:Embryo, Mammalian / Q000187:drug effects / Q000502:physiology*; D047108:Embryonic Development / Q000187:drug effects / Q000502:physiology; D005260:Female; D007976:Leupeptins / Q000494:pharmacology*; D051379:Mice; D053652:Nuclear Transfer Techniques; D009865:Oocytes / Q000187:drug effects* / Q000502:physiology / Q000648:ultrastructure; D017231:Proto-Oncogene Proteins c-mos / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D000095043:Cyclin-Dependent Kinase-Activating Kinase
D015853:Cysteine Proteinase Inhibitors; D007976:Leupeptins; D017231:Proto-Oncogene Proteins c-mos; D018844:Cyclin-Dependent Kinases; C072553:benzyloxycarbonylleucyl-leucyl-leucine aldehyde; D000095043:Cyclin-Dependent Kinase-Activating Kinase